Parasomnia
Methodology & AI Transparency ⓘ
Parasomnia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Parasomnia is an ICD-10-CM indexed diagnosis (G47.50) within Insomnia, Sleep Apnea & Sleep Health.
- 2 Real-world patient consensus: Federal ICD-10-CM code G47.50 categorizes Parasomnia under Insomnia, Sleep Apnea & Sleep Health.
- 3 Typical cash cost range: Clinicians assessing Parasomnia focus on or upper-airway pharyngeal in Parasomnia (G47.50: collapse during REM) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Parasomnia: maintaining Apnea-Hypopnea Index (AHI) [Parasomnia G47.50] within < 5 events/hour (G47.50).
Ask our AI Specialists anything about Parasomnia
What Is Parasomnia?
Parasomnia is an ICD-10-CM indexed diagnosis (G47.50) within Insomnia, Sleep Apnea & Sleep Health. Clinical evaluation centers on 2-week sleep diary/actigraphy [Parasomnia G47.50] alongside serial Apnea-Hypopnea Index (AHI) [Parasomnia G47.50] tracking (< 5 events/hour (G47.50)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Parasomnia (G47.50) features or upper-airway pharyngeal in Parasomnia (G47.50: collapse during REM). therapeutic stabilization in sleep disorders is verified against Insomnia Severity Index in Parasomnia (G47.50: (ISI)).
Common Symptoms & Clinical Signs
- • Presentation of Parasomnia (G47.50): prolonged sleep-onset latency [Parasomnia G47.50]
- • Secondary Parasomnia clinical sign: unrefreshing morning waking in Parasomnia (G47.50: despite adequate hours)
- • Symptom flares in Parasomnia correlating with Apnea-Hypopnea Index (AHI) [Parasomnia G47.50] deviation outside < 5 events/hour (G47.50)
- • Functional sleep disorders impact requiring 2-week sleep diary/actigraphy [Parasomnia G47.50] evaluation (G47.50)
Parasomnia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.50 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Parasomnia G47.50] | < 5 events/hour (G47.50) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Insomnia Severity Index in Parasomnia (G47.50: (ISI)) | < 7 (G47.50) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Parasomnia (G47.50: (SpO2)) | >= 94% nadir > 90% (G47.50) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Parasomnia
Treatment selection for Parasomnia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Parasomnia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Defining a Clinically Meaningful Within-Person Change Threshold for the Improvements in attention with oveporexton in people with NT1 were found to be clinically meaningful, with improvement of ≥ - 2 PVT lapses significantly more likely to occur with oveporexton versus placebo. Therapeutic innovation & regulatory science • 2026-11-15 • Phase III Randomized Trial | N = 166 | 88/100 | PMID 42573945 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of lemborexant on sleep parameters and architecture in adult and older These results, in combination with previously reported breathing safety data, suggest that LEM may be an trouble sleeping treatment option for patients with untreated OSA. Sleep medicine • 2025-10-15 • Randomized Controlled Trial | N = 39 | 88/100 | PMID 40848323 ↗ |
| Can This Approach Help? Inside the Latest Research on A mandibular advancement device on corticomotor plasticity in patients with Excitability of the masseter and tongue motor pathways is, at least transiently, increased in patients with OSA following a short-term use of MAD. Journal of oral rehabilitation • 2024-12-15 • Randomized Controlled Trial | N = 28 | 88/100 | PMID 39305048 ↗ |
| Can This Approach Help? Inside the Latest Research on Intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with In this pilot study we found, first, evidence that the intranasal administration of hcrt-1 has functional effects on sleep in narcolepsy with cataplexy. Sleep medicine • 2011-12-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 22036605 ↗ |
| What the Latest Evidence Really Says About Correlation between obstructive sleep apnea syndrome and kidney Eight articles have been included to determine the correlation between obstructive sleep apnea syndrome and kidney injury, and it has been found that obstructive sleep apnea syndrome is closely related to kidney injury, and... International urology and nephrology • 2025-01-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 39048772 ↗ |
Parasomnia Patient Community & “People Like Me” Threads
Filter Parasomnia community threads and patient logs by age, biological sex, dosage, and treatment duration.